Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $97,715.48 in Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,534 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total value of $97,715.48. Following the sale, the insider now owns 110,673 shares of the company’s stock, valued at approximately $799,059.06. This trade represents a 10.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Francesca Barone also recently made the following trade(s):

• On Wednesday, January 8th, Francesca Barone sold 13,673 shares of Candel Therapeutics stock. The stock was sold at an average price of $8.22, for a total value of $112,392.06.

Candel Therapeutics Trading Down 13.4 %

NASDAQ:CADL opened at $6.66 on Friday. Candel Therapeutics, Inc. has a 12 month low of $1.16 and a 12 month high of $14.60. The stock has a 50 day moving average of $6.61 and a two-hundred day moving average of $6.28. The firm has a market cap of $216.32 million, a P/E ratio of -3.85 and a beta of -1.20.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $19.00 price objective (up from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 DIFC Ltd acquired a new position in shares of Candel Therapeutics during the 2nd quarter worth approximately $31,000. FMR LLC acquired a new position in shares of Candel Therapeutics during the 3rd quarter worth approximately $46,000. MetLife Investment Management LLC acquired a new position in shares of Candel Therapeutics during the 3rd quarter worth approximately $87,000. Atom Investors LP acquired a new position in shares of Candel Therapeutics during the 3rd quarter worth approximately $103,000. Finally, State Street Corp boosted its holdings in shares of Candel Therapeutics by 4.1% during the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock worth $3,410,000 after purchasing an additional 19,207 shares during the last quarter. 13.93% of the stock is currently owned by institutional investors and hedge funds.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.